clinic
symptom
cmv
infect
diseas
may
vari
asymptomat
form
system
syndrom
fever
leukothrombocytopenia
increas
hepat
transaminas
malais
frank
diseas
sign
symptom
organ
involv
usual
gastrointestin
tract
lung
liver
central
nervou
system
two
major
categori
patient
risk
need
close
monitor
cmv
reactiv
patient
receiv
allograft
monitor
least
day
longer
period
surveil
recommend
patient
sever
graftversushost
diseas
gvhd
receiv
haploident
cord
blood
unrel
transplant
patient
treat
alemtuzumab
monitor
least
month
end
treatment
manag
cmv
infect
hsct
recipi
includ
follow
primari
infect
may
prevent
select
right
donor
patient
found
seroneg
cmvseroneg
donor
select
possibl
safe
blood
product
cmvseroneg
allogen
stem
cell
transplant
patient
cmvseroneg
donor
receiv
leukocytedeplet
cmv
seroneg
blood
product
onlydur
past
decad
two
major
improv
remark
impact
prevent
infect
patient
develop
cmv
diseas
first
factor
modifi
outcom
cmv
infect
possibl
diagnos
infect
earli
phase
test
great
sensibl
specif
cmv
antigenemia
recent
cmv
quantit
pcr
strongli
recommend
diagnosi
cmv
infect
peripher
blood
second
factor
introduct
new
drug
potenti
effect
cmv
includ
ganciclovir
valganciclovir
foscarnet
cidofovir
possibl
rapid
diagnost
test
highli
effect
compound
led
develop
new
treatment
strategi
name
cmv
prophylaxi
preemptiv
treatment
cmv
prophylaxi
ganciclovir
effect
strategi
prevent
cmv
diseas
could
use
subgroup
allogen
hsct
patient
high
risk
cmv
diseas
preemptiv
treatment
base
posit
antigenemia
pcr
either
ganciclovir
foscarnet
use
firstlin
preemptiv
treatment
wherea
valganciclovir
may
consid
altern
therapi
particularli
lowrisk
patient
except
intestin
gvhd
allogen
hsct
set
copi
blood
may
consid
threshold
start
preemptiv
treatment
import
underscor
fact
approxim
onethird
patient
may
present
rise
cmv
viru
load
even
initi
treatment
consid
sign
treatment
failureth
treatment
establish
cmv
diseas
base
use
ganciclovir
foscarnet
addit
immun
globulin
cidofovir
combin
ganciclovir
foscarnet
use
secondlin
therapi
question
still
pend
first
drug
toxic
nephrotox
myelosuppress
repres
limit
factor
extens
use
medic
effect
treatment
cmv
infect
second
drug
resist
ganciclovir
result
mutat
either
phosphotransferas
gene
kinas
product
respons
ganciclovir
phosphoryl
activ
gene
code
dna
polymeras
may
repres
clinic
signific
problem
patient
interest
observ
recent
report
analyz
consecut
patient
acut
myeloid
leukemia
receiv
allogen
hsct
signific
lower
risk
leukem
relaps
found
among
patient
develop
posit
cmv
antigenemia
compar
reactiv
viru
antileukem
effect
cmv
reactiv
remain
independ
variabl
even
multivari
analysi
consid
known
risk
factor
gvhd
diseas
risk
group
reactiv
detect
blood
hsct
patient
clinic
syndrom
associ
infect
includ
delay
engraft
fever
rash
hepat
pneumon
gastroduoden
enceph
diseas
associ
patient
hematolog
malign
undergon
hsct
enceph
may
consid
seriou
clinic
syndrom
although
rare
event
case
describ
literatur
far
usual
month
post
hsct
appar
enceph
due
common
cord
blood
human
leukocyt
antigenmismatch
graft
clinic
pictur
includ
shortterm
memori
loss
seizur
hyponatremia
csf
pleocytosi
elev
csf
protein
level
diagnosi
infect
may
obtain
use
quantit
pcrbase
evalu
dna
copi
per
ml
whole
blood
plasma
serum
nevertheless
chromosom
integr
exclud
preval
vertic
transmiss
motherfath
character
persist
high
dna
level
copi
per
ml
whole
blood
whether
viremia
increas
mortal
remain
determin
studi
found
associ
mortal
infect
like
frequent
occurr
spontan
resolv
viremia
multifactori
interact
immun
defici
gvhd
concomit
complic
hsct
recipi
develop
viremia
seriou
lifethreaten
event
associ
ebv
infect
occurr
posttranspl
lymphoprolif
diseas
heterogen
group
ebv
diseas
neoplast
lymphoprolifer
caus
iatrogen
suppress
tcell
function
major
risk
factor
posttranspl
lymphoprolif
diseas
includ
unrelatedmismatch
tcell
deplet
particular
atg
use
cord
blood
ebv
serolog
mismatch
recipi
neg
donor
posit
accord
consider
prospect
monitor
ebvdnaemia
strongli
recommend
highrisk
patient
week
month
transplant
longer
patient
gvhd
data
regard
prophylaxi
ebv
although
bcell
deplet
might
potenti
reduc
risk
ebv
diseas
preemptiv
approach
ebvdnaemia
repres
present
standard
care
base
administr
rituximab
associ
reduct
system
immunosuppress
whenev
possibl
respons
therapi
could
identifi
decreas
ebvdnaemia
least
one
log
magnitud
first
week
treatment
immunocompromis
host
respiratori
virus
may
associ
mani
symptom
span
cold
episod
croup
bronchiol
children
exacerb
asthma
frank
pneumonia
adult
incid
respiratori
viru
infect
differ
significantli
among
studi
observ
underscor
studi
ljungman
et
incid
vari
european
particip
center
lymphopenia
seem
import
risk
factor
progress
lower
respiratori
diseas
among
viral
infect
worthwhil
recal
hbv
reactiv
common
follow
chemotherapi
purin
analog
monoclon
antibodi
rituximab
alemtuzumab
allogen
hsct
fact
immun
suppress
may
lead
increas
hbv
replic
wherea
immun
reconstitut
within
week
month
follow
recoveri
chemotherapyimmunosuppress
treatment
may
associ
flare
hepat
b
manifest
hepatocellular
injuri
conclus
viral
infect
remain
seriou
complic
patient
hematolog
malign
recent
advanc
rapid
diagnost
method
grow
number
antivir
agent
allow
effici
manag
strategi
pathogen
